Adlai Nortye to Discuss AN4035 Preclinical Findings at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Treatments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 22 2025
0mins
Source: Newsfilter
Presentation Announcement: Adlai Nortye Ltd. will present its novel CEACAM5-targeting antibody-drug conjugate (ADC), AN4035, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025.
Key Findings: AN4035 showed strong cytotoxicity in specific cancer cell lines, achieved a 73% objective response rate in a patient-derived xenograft trial, and demonstrated a favorable toxicology profile in preclinical studies.
Therapeutic Potential: The ADC is designed to minimize systemic toxicities associated with current pan-RAS(ON) inhibitors, aiming to improve efficacy and broaden the therapeutic window for treating RAS-addicted tumors.
Company Overview: Adlai Nortye is a clinical-stage biotechnology company focused on innovative cancer therapies, with a portfolio that includes next-generation PD-1/L1 modulation and RAS-targeted therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANL
About ANL
Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SanDisk Reports Strong Q2 Results, Shares Surge
- Strong Earnings Report: SanDisk's second-quarter results exceeded expectations, leading to a 20.9% surge in pre-market trading, with shares reaching $652.00, indicating strong market confidence in its financial health.
- Optimistic Q3 Guidance: The company forecasts third-quarter revenue between $4.4 billion and $4.8 billion, with non-GAAP diluted earnings per share expected to be between $12 and $14, suggesting ongoing improvement in growth potential and profitability.
- Joint Venture Extension: SanDisk announced the extension of its joint venture with Japan's Kioxia Corp. until December 31, 2034, further solidifying their strategic partnership in storage technology and enhancing market competitiveness.
- Positive Market Reaction: The significant rise in stock price reflects investor optimism about the company's future prospects, which may also attract more institutional investors, thereby elevating the company's standing in the industry.
Continue Reading
Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%
- Stock Surge: Baidu's announcement of a proposed spinoff of Kunlunxin (Beijing) Technology Co., Ltd. H shares for a separate listing on the Hong Kong Stock Exchange led to a 12.3% increase in its stock price to $146.69 in pre-market trading, indicating strong market enthusiasm for this strategic move.
- Spinoff Strategy: The spinoff aims to enhance Kunlunxin's independence and market valuation, which is expected to provide Baidu with more flexible capital operations and resource allocation, thereby strengthening its competitive position in the technology sector.
- Market Reaction: The spinoff news has sparked investor excitement, with the significant rise in Baidu's stock reflecting confidence in its future growth potential and likely attracting more institutional investors to its shares.
- Industry Impact: By pursuing this spinoff, Baidu can focus more on its core business while providing Kunlunxin with greater development space, which is anticipated to drive innovation and investment activity across the technology industry.
Continue Reading